[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610475":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":31,"responsibleParty":49,"collaborators":53,"id":59,"slug":31,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":31,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":31,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":31,"overallStatus":78,"whyStopped":31,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":31},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Provider nudge only","ACTIVE_COMPARATOR","Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the EHR.",[13],"Behavioral: Provider nudge",{"label":15,"type":16,"description":17,"interventionNames":18},"Provider nudge + Patient nudge","EXPERIMENTAL","In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist delivered nudges (e.g., text messages) 1-7 days before the visit to encourage fixed dose combination medications.",[13,19],"Behavioral: Patient nudge",{"label":21,"type":16,"description":22,"interventionNames":23},"Provider nudge + Pharmacist Virtual Visit","In addition to provider nudges (Provider nudge only arm), patients will receive pharmacist counseling and prescribing delivered via virtual encounters after the visit.",[13,24],"Behavioral: Pharmacist Virtual Visit",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"BEHAVIORAL","Provider nudge","Pharmacists will deliver targeted nudges to providers through clinical decision support integrated into the electronic health record (EHR)",[15,21,9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Patient nudge","Patients will receive pharmacist-delivered nudges (e.g., text messages) 1-7 days before their visit to encourage fixed-dosed combinations",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Pharmacist Virtual Visit","Patients will receive pharmacist counseling and prescribing delivered via virtual encounters after their visit",[21],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Julie Lauffenburger, PharmD, PhD","CONTACT","617-525-8865","jlauffenburger@bwh.harvard.edu",{"name":47,"role":43,"phone":31,"phoneExt":31,"email":48},"Rasha Khatib, PhD, MHS","rasha.alkhatib@aah.org",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Julie Lauffenburger","Associate Professor",[54,57],{"name":55,"class":56},"National Institute on Aging (NIA)","NIH",{"name":58,"class":6},"Wake Forest University Health Sciences","100610475",false,"NCT07228065","Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control","Pharmacy-led Intervention to Increase the Adoption of Fixed-dose Single Pill Blood Pressure Lowering Medications: Hybrid Effectiveness-Implementation Trial","Inclusion Criteria:\n\n* patients with documented hypertension diagnosis\n* had an elevated ambulatory blood pressure reading during the qualifying visit (systolic \\>140 mmHg or diastolic \\>90 mmHg\n* have an upcoming scheduled visit\n* have an active prescription for 1 blood pressure lowering medication with a fixed-dose combination (FDC) alternative\n\nExclusion Criteria:\n\n* have received a prescription for a FDC in the preceding two years\n* reside in a nursing home\n* have a documented allergy to any FDC components\n* are pregnant\n* preferred language is not English or Spanish, defined as documentation in the EHR indicating a primary language other than English or Spanish, or a documented request for an interpreter in a language other than Spanish\n* have a diagnosis of heart failure or renal failure, given that antihypertensive management in these populations typically requires disease-specific regimens and more frequent treatment adjustments","ALL","18 Years","80 Years",{"count":69,"type":70},720,"ESTIMATED","INTERVENTIONAL",[73],"NA","The proposed study is an effectiveness-implementation hybrid type II trial designed to evaluate the impact of provider- and patient-directed interventions on FDC use. The trial will test the effectiveness of theory-driven nudges tailored to address provider and patient barriers. All interventions will be pharmacist-driven, with pharmacists delivering information via nudges to providers and via nudges or more intensive interventions (i.e., CPA) to patients. Data to evaluate outcomes will be extracted from electronic health records.",[76,77],"Hypertension","Primary Care","NOT_YET_RECRUITING","2026-06-17",{"date":81,"type":82},"2026-06-18","ACTUAL",{"date":84,"type":70},"2026-07-31",{"date":86,"type":70},"2027-06-30",{"name":5,"class":6}]